地舒单抗联合高剂量特立帕肽治疗绝经后骨质疏松(DATA-HD):随机对照4期试验
DATA-HD是一项开放标签随机对照4期试验,纳入76例绝经后骨质疏松女性,比较特立帕肽20μg与40μg联合地舒单抗治疗。高剂量联合方案可能更有效恢复骨骼完整性。
要点
- 特立帕肽40μg联合地舒单抗较20μg联合方案更显著增加腰椎和髋部aBMD。
- 高剂量组严重不良事件发生率较低(5% vs 18%),但需关注安全性。
核心结论
- 特立帕肽40μg联合地舒单抗治疗绝经后骨质疏松,腰椎和髋部aBMD增幅显著大于特立帕肽20μg联合地舒单抗。
研究设计与样本
- DATA-HD为开放标签、随机对照4期试验,在美国马萨诸塞州总医院进行,纳入76例绝经后骨质疏松女性,随机1:1接受特立帕肽20μg或40μg每日皮下注射9个月,第3个月起两组均加用地舒单抗60mg每6个月皮下注射共12个月。
主要发现
- 20μg组30例(77%)和40μg组29例(78%)发生不良事件,严重不良事件分别为7例(18%)和2例(5%)。
- 最常见不良事件:20μg组为关节痛(38%)、肌肉痉挛(38%)和疲劳(31%);40μg组为疲劳(38%)、恶心(43%)和关节痛(46%)。
临床怎么用
- 对于绝经后骨质疏松患者,特立帕肽40μg联合地舒单抗可能比标准剂量联合方案更大幅度和快速地增加骨密度。
局限性
- 研究为开放标签设计,样本量较小(76例随机),随访15个月,长期疗效和安全性需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Denosumab and Teriparatide Administration (DATA) study, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral density (BMD) than with either drug alone. We aimed to assess whether administration of denosumab with high dose teriparatide would stimulate larger increases in bone mass than those observed in the DATA study. METHODS: DATA-HD was an open-label, randomised, controlled phase 4 trial done at Massachusetts General Hospital. Eligible women were postmenopausal women (at least 36 months since last menses or since hysterectomy with a follicle-stimulating hormone concentration of ≥40 U/L) with osteoporosis. Participants were randomly assigned (1:1) to receive teriparatide 20 μg (standard dose) or 40 μg (high dose) daily via subcutaneous injection for 9 months. At 3 months, both groups were started on denosumab 60 mg every 6 months via subcutaneous injection for 12 months. Areal BMD (aBMD) was measured at 0, 3, 9, and 15 months. Treatment was given open label, but outcome assessors were masked. The primary endpoint was percentage change from baseline in spine areal BMD (aBMD) at 15 months. Women who completed at least one study visit after baseline were included in the modified intention-to-treat analysis. Safety was assessed in all randomly assigned participants. This study is registered with ClinicalTrials.gov, number NCT02176382. FINDINGS: Between Oct 15, 2014, and June 10, 2016, 269 women were assessed for eligibility. 76 participants were randomly assigned to 20 μg teriparatide (n=39) or 40 μg teriparatide (n=37), of whom 69 completed at least one post-baseline visit. At 15 months, mean spine aBMD had increased to a significantly greater extent in the 40 μg group (17·5% [SD 6·0] increase) than the 20 μg group (9·5% [3·2]; difference 8·1%, 95% CI 5·5 to 10·6, p<0·0001). Mean femoral neck aBMD had also increased to a greater extent in the 40 μg group (6·8% [SD 4·1] increase) than the 20 μg group (4·3% [3·7]; difference 2·5%, 0·5 to 4·5, p=0·04), as did mean total hip aBMD (40 μg group, 6·1% [3·4] increase; 20 μg group, 3·9% [2·9] increase; difference 2·2%, 0·6 to 3·8, p<0·0001). 30 (77%) of 39 participants in the 20 μg group and 29 (78%) of 37 participants in the 40 μg group had an adverse event, and seven (18%) and two (5%) patients had serious adverse events. The most frequent adverse events were joint pain (15 [38%]), muscle cramp (15 [38%]), and fatigue (12 [31%]) in the 20 μg group group and fatigue (14 [38%]), nausea (16 [43%]), and joint pain (17 [46%]) in the 40 μg group. No deaths were reported. INTERPRETATION: Combined treatment with teriparatide 40 μg and denosumab increases spine and hip BMD more than standard combination therapy. This large and rapid increase in bone mass suggest that this high dose regimen might provide a method of restoring skeletal integrity in patients with osteoporosis. FUNDING: National Institutes of Health and the Dart Foundation.
引用
- Tsai JN, Lee H, David NL, et al. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019. PMID: 31447409. doi:10.1016/S2213-8587(19)30255-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。